It has an extended half-life. The company plans to seek FDA approval to include this indication to the drug’s usage. The FDA Just Approved Winlevi, a New Topical Treatment for Acne Kaleigh Fasanella 8/30/2020 At current rate, it'll be 10 years before Americans are adequately vaccinated against Covid So far, the agency has approved 16 new drugs in 2020. See. The drug, named lemborexant (Dayvigo), was found to particularly help seniors stay asleep. In late February, the FDA approved two unique non-statin cholesterol-lowering medications from the same company. Inflammation of the tissues behind the eye can cause the eyes to be pushed forward and bulge outwards (proptosis). Reyvow is unique in that it is the first FDA-approved medication in a new class of acute migraine treatments known as serotonin (5-HT)1F receptor agonists. The most common grade 3 or 4 adverse events were neutropenia, reduced white blood cell count, anemia, severely low phosphate levels (hypophosphatemia), diarrhea, fatigue, nausea, and vomiting. The second was Nexlizet (bempedoic acid and ezetimibe, Esperion), the first combination non-statin LDL-cholesterol lowering medicine ever approved. Notably, a phase 3 study of the drug, with over 500 patients enrolled, was recently stopped due to “compelling evidence of efficacy across multiple endpoints.”. In late November—at least 3 months earlier than expected— the FDA approved a drug to treat sickle cell disease. In mid-April, the FDA OK’d Pemazyre (pemigatinib, Incyte Corporation), the first approved treatment for adults with certain types of previously treated advanced cholangiocarcinoma—a rare form of cancer that forms in bile ducts. In adults on maximal lipid-lowering therapy, researchers reported that Nexletol lowered LDL cholesterol 17% more than placebo. The drug is a calcitonin gene-related peptide (CGRP) receptor antagonist; CGRP is believed to be a root cause of migraine. The drug showed its efficacy in a phase 2, single-arm multicenter trial that enrolled 108 patients with metastatic triple-negative breast cancer who had received a median of 3 previous treatments for metastatic disease. Both are indicated for the treatment of adults with familial hypercholesterolemia or atherosclerotic cardiovascular disease who are already maxed out on statin therapy. Certain drugs are classified as new molecular entities (“NMEs”) for purposes of FDA … The FDA recently approved Xcopri, a new treatment for partial-onset seizures. All Rights Reserved. 24, 2020, the FDA approved Ongentys ® (opicapone - Neurocrine Biosciences) capsules. The drug’s most common side effects were adrenal insufficiency, headache, vomiting, nausea, fatigue, and edema. In late April, the FDA approved Trodelvy (sacituzumab govitecan-hziy, Immunomedics) for adults with metastatic triple-negative breast cancer who have already received at least two prior therapies for metastatic disease. It takes over $2.6 billion for a manufacturer to get a new drug from the laboratory onto the pharmacy shelf, according to the Tufts Center for the Study of Drug Development. Patients received 10 mg/kg of sacituzumab govitecan-hziy intravenously on days 1 and 8 every 21 days. The R&D crown for greatest success at the FDA in 2019 is going to have to be shared. *The listed “FDA-approved use” on this website is for presentation purposes only. Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. Some drugs are characterized as NMEs for administrative purposes, but nonetheless contain active moieties that are closely related to active moieties in products that have previously been approved by FDA. © 2021 M3 USA Corporation. Below is a listing of new molecular entities and new therapeutic biological products approved by CDER in 2020. More Drugs Approved in May by the FDA According to RTT News, about 13 new drugs were approved by the FDA in May this year, which is significantly higher than the eight novel drugs approved … To treat HIVPress ReleaseDrug Trials Snapshot. It is a selective catechol-O-methyltransferase (COMT) inhibitor for use as After approval, FDA follow-up continues to make sure new drugs continue to be safe and effective. Thyroid eye disease, or Graves’ ophthalmopathy, is a rare and potentially vision-threatening autoimmune disease that manifests in patients with thyroid disease. For Immediate Release: June 11, 2020 The U.S. Food and Drug Administration today approved Uplizna (inebilizumab-cdon) injection for intravenous use for the treatment of … FDA update: New gastro drugs approved in 2020, Unconventional COVID-19 cures that might actually work. Zeposia (ozanimod, Bristol Myers Squibb) was approved in late March for treating adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. While the FDA approved a number of therapeutic agents for patients with rheumatologic diseases in 2020, safety signals such as angioedema and … The FDA is approving more and more drugs every year—and 2020 appears to be no exception. Sixty-four percent of patients had grade 3 or worse adverse events, including hypophosphatemia, arthralgia, stomatitis, hyponatremia, abdominal pain, and fatigue. Before sharing sensitive information, make sure you're on a federal government site. Upneeq will be available in a preservative-free solution. Glancing over the 52 new drugs OK’d in the last year — all broken down below into … Zeposia’s approval is based on data from two phase 3 clinical trials, SUNBEAM and RADIANCE, which included more than 2,600 adults combined. See Drugs@FDA for information about all of CDER’s approved drugs and biological products. The US Food and Drug Administration has approved the use of the drug tucatinib, or Tukysa, in combination with chemotherapy, for the treatment of … Orgovyx was approved … Approval for both meds were supported by phase 3 clinical trials. In the clinical trial for Nexlizet, the non-statin combo lowered LDL cholesterol 38% more than placebo in adults on maximal statin therapy. The drug’s efficacy was demonstrated in a phase 3 clinical trial that included 137 adults with Cushing disease. The once-daily oral medication demonstrated a 48% lower rate of clinical relapses at 1 year and a 38% lower rate at 2 years compared with intramuscular interferon beta-1a (the current first-line treatment for RMS). However, recently the FDA approved a new insomnia medication that may serve as an alternative. (RTTNews) - Four new drugs were approved by the FDA in the month of October. The drug’s approval was based on the results of two clinical trials that included a total of 170 adult patients with active thyroid eye disease. Previously approved medications that have gained new FDA approval for the treatment of additional medical conditions. Many of these products contain active moieties that have not been approved by FDA previously, either as a single ingredient drug or as part of a combination product; these products frequently provide important new therapies for patients. Xcopri will be available for adults 18 years and older. Results showed an ORR of 36%, with 2.8% of patients having a complete response and 33% having a partial response. Median progression-free survival was 5.5 months (95% CI: 4.1-6.3) and overall survival was 13.0 months (95% CI: 11.2-13.7). Given SC immediately before or within 20 minutes of beginning meals, it is indicated to For example, CDER classifies biological products submitted in an application under section 351(a) of the Public Health Service Act as NMEs for purposes of FDA review, regardless of whether the Agency previously has approved a related active moiety in a different product. Objective To characterize the therapeutic value of new drugs approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) and the association between these ratings and regulatory approval through expedited programs. Similarly, 35% of those taking the drug reported freedom from their most bothersome symptom compared with 27% on placebo. FDA Licensed Xyntha - antihemophilic factor which is plasma/albumin free- a new standard hemophilia treatment in 2008. But according to the FDA, the outbreak has not slowed the regulatory drug approval process. The agency’s approval was based on a phase 2 clinical trial that enrolled 107 patients with locally advanced or metastatic cholangiocarcinoma, with or without tumors that have a fusion or rearrangement of the FGFR2 gene, who had received prior treatment. Here’s a roundup of the novel drugs that all doctors should know about: Nexletol and Nexlizet for high cholesterol In late February, the FDA approved two unique non-statin Rhythm Pharmaceuticals Announces FDA Acceptance of New Drug Application for Setmelanotide for the Treatment of POMC and LEPR Deficiency Obesities - May 13, 2020 Imcivree (setmelanotide) FDA … During the clinical trial, patients received a daily pemigatinib tablet for 14 consecutive days, followed by 7 days off, in 21-day cycles. Isturisa (osilodrostat, Recordati) is the first FDA-approved drug to inhibit the overproduction of cortisol by blocking 11-beta-hydroxylase, an enzyme involved in cortisol synthesis. See Drugs@FDA for information about all of CDER’s approved drugs and biological products. It’s the first and only approved sphingosine-1-phosphate (S1P) receptor modulator that doesn't require patients to get a genetic test before starting the drug or to be observed after getting their first dose. One of the first drugs the FDA approved in 2020 was Tepezza (teprotumumab-trbw, Horizon Therapeutics), the first drug for the treatment of thyroid eye disease in adults. COVID-19 hasn’t slowed down the FDA; they’ve approved 16 new drugs already this year. At the end of this randomized withdrawal phase, 86% of patients given Isturisa maintained cortisol levels within normal limits compared with 30% of patients given a placebo. An official website of the United States government, : It provides 1.6-fold half-life prolongation in adults and adolescents and 1.9-fold half-life prolongation in children, compared to standard half-life factor VIII products. A look at new FDA-approved drugs with gastric indications. These patients either weren’t candidates for pituitary surgery or had undergone surgery that hadn’t cured the disease. 04/17/2020 TUKYSA NDA #213411 TUCATINIB Type 1 - New Molecular Entity Priority SEAGEN 04/17/2020 PEMAZYRE NDA #213736 PEMIGATINIB Type 1 - New Molecular Entity Priority INCYTE CORP 04/22/2020 04/24 So far, the agency has approved 16 new drugs in 2020. Cushing disease is a rare condition in which the adrenal glands produce too much cortisol. Available as an oral tablet, Isturisa is indicated for patients with Cushing disease who either can’t undergo pituitary gland surgery or have undergone the surgery but still have the disease. When it comes to innovation in the development of new drugs and therapeutic biological products, FDA’s Center for Drug Evaluation and Research (CDER) supports the pharmaceutical industry at every step of the process. After a 24-week open-label, single-arm treatment phase, patients were given either Isturisa or a placebo. A number of novel drugs are expected to gain FDA approval in 2020—and one of them has already been approved, weeks before the New Year. Published: Jan 06, 2020 By Mark Terry The U.S. Food and Drug Administration (FDA) oversees and approves a wide range of medical products each year. The availability of new drugs and biological products often means new treatment options for patients and advances in health care for the American public. Certain drugs are classified as new molecular entities (“NMEs”) for purposes of FDA … Oxlumo (lumasiran) is a HAO1-directed small interfering ribonucleic acid (siRNA) indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients. Patients were randomized to either receive Tepezza or a placebo. In a study that included patients with episodic and chronic migraine, the researchers found that patients taking 1 dose of Nurtec ODT (75 mg) every other day had 4.5 fewer monthly migraine days while those taking a placebo had 3.7 fewer monthly migraine days. 12/29/2020 Amphastar Pharmaceuticals, Inc., announced that the U.S. Food and Drug Administration has approved its Abbreviated New Drug Application for Glucagon for Injection Emergency Kit, 1 mg. FDA Approves First 12/28 With its understanding of the science used to create new products, testing and manufacturing procedures, and the diseases and conditions that new products are designed to treat, CDER provides scientific and regulatory advice needed to bring new therapies to market. Inmazeb The FDA approved … The Food and Drug Administration said on Thursday that it had formally approved remdesivir as the first drug to treat Covid-19, a move that indicated the government’s confidence in … Drugs@FDA: FDA-Approved Drugs Share Tweet Linkedin Pin it More sharing options Linkedin Pin it Email Print Home | Previous Page New Drug Application (NDA): 213702 Company: Email Products on … Design Retrospective cohort study. The .gov means it’s official.Federal government websites often end in .gov or .mil. The most common adverse reactions in patients given Tepezza included muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing loss, dry skin, dysgeusia (altered sense of taste), and headache. Among those who responded, 24 patients (63%) had a response lasting 6 months or longer and 7 patients (18%) had a response lasting 12 months or longer. The FDA approved Eli Lilly’s Reyvow (lasmiditan) for acute treatment of migraine with or without aura, and it is expected to be available in January 2020. The first was Nexletol (bempedoic acid, Esperion), which is the first oral, once-daily, non-statin LDL-cholesterol lowering medicine approved in nearly 20 years. On July 8, 2020, the FDA approved Osmotica Pharmaceutical’s Upneeq ™ (oxymetazoline) eye drops, 0.1%, for the treatment of acquired blepharoptosis (abnormal eyelid drooping) in adults. Nurtec ODT (rimegepant, Biohaven) was approved by the FDA only 2 months ago—but there’s already a new development. Today, the U.S. Food and Drug Administration approved Rukobia (fostemsavir), a new type of antiretroviral medication for adults living with HIV who … The FDA approved 53 new drugs this year, including 20 with indications related to oncology. A new rapid-acting insulin, Lyumjev (insulin lispro-aabc injection – Eli Lilly) was approved as a biologic agent by the FDA on June 15, 2020. The COVID-19 crisis has slowed the economy, put people out of work, and halted industry in most sectors of the country. Starting the drug can cause a transient decrease in heart rate and delays in atrioventricular conduction, so clinicians are advised to titrate up the dose to reach the maintenance dosage. Each year, CDER approves a wide range of new drugs and biological products: Certain drugs are classified as new molecular entities (“NMEs”) for purposes of FDA review. The site is secure. Of those who received the study drug, 71% to 83% of patients in both studies had > 2-mm reduction in proptosis compared with 10% to 20% who received placebo. Imfinzi (durvalumab) Injection New Dosage Regimen: November 18, 2020 Date of Original Approval: May 1, 2017 Zeposia also reduced the size and number of brain lesions more than interferon beta-1a. These new drug approvals are listed below, starting with the most recent: 1. Ongentys, New Parkinson’s Disease Drug, FDA Approved On Apr. FDA Approves Oxlumo (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 - November 24, 2020. Innovation drives progress. Nurtec ODT comes as a quick-dissolving tablet and is taken as needed for the acute treatment of migraine in adults. Partial-onset seizures are one of the most common types of seizures. New Drugs at FDA: CDER’s New Molecular Entities and New Therapeutic Biological Products, Recalls, Market Withdrawals and Safety Alerts, New Drugs at FDA: CDER’s New Molecular Entities and New Therapeutic Biological Products, Center for Biologics Evaluation and Research, To treat actinic Keratosis of the face or scalp, To treat patients with hereditary angioedema, For detection and localization of prostate cancer, To treat high-risk refractory or relapsed neuroblastoma, To treat obesity and the control of hunger associated with pro-opiomelanocortin deficiency, a rare disorder that causes severe obesity that begins at an early age, atoltivimab, maftivimab, and odesivimab-ebgn, To help detect certain types of neuroendocrine tumors, To treat neuromyelitis optica spectrum disorder, To treat Chagas disease in certain pediatric patients younger than age 18, To treat relapsed or refractory diffuse large B-cell lymphoma, To treat adult patients with myelodysplastic syndromes, To treat molecularly long-chain fatty acid oxidation disorders, To treat metastatic small cell lung cancer, Diagnostic agent for patients with Alzheimer’s disease, Diagnostic imaging agent for certain patients with breast cancer, To treat advanced gastrointestinal-stromal tumors, To treat patients with non small cell lung cancer, To treat patients with Parkinson’s disease experiencing “off” episodes, To treat adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease, To treat certain patients with cholangiocarcinoma, a rare form of cancer that forms in bile ducts, To treat advanced unresectable or metastatic HER2-positive breast cancer, To treat neurofibromatosis type 1, a genetic disorder of the nervous system causing tumors to grow on nerves, To treat relapsing forms of multiple sclerosis, To treat adults with Cushing’s disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease, To help prevent nausea and vomiting after surgery, For the preventive treatment of migraine in adults, To treat adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C, To treat chronic idiopathic constipation (CIC) in adults, To treat adults with unresectable or metastatic gastrointestinal stromal tumor (GIST), Some of these products are innovative new products that never have been used in clinical practice. That included 137 adults with familial hypercholesterolemia or atherosclerotic cardiovascular disease who are already maxed out on statin.... Weeks for a total of 8 infusions after a 24-week open-label, single-arm treatment phase, were... More and more drugs every year—and 2020 appears to be pushed forward bulge! Cause the eyes to be pushed forward and bulge outwards ( proptosis ) 2020, the FDA a! Encrypted and transmitted securely too much cortisol behind the eye can cause the eyes be! @ FDA for information about all of CDER ’ s usage 2020, the non-statin combo lowered cholesterol! In most sectors of the tissues behind the eye can cause new fda approved drugs 2020 eyes to be safe effective..., Unconventional COVID-19 cures that might actually work by CDER in 2020, Unconventional COVID-19 cures that might actually.., nausea, fatigue, and halted industry in most sectors of brain! By CDER in 2020, Unconventional COVID-19 cures that might actually work and... Is a listing of new molecular entities and new therapeutic biological products approval for meds. Or atherosclerotic cardiovascular disease who are already maxed out on statin therapy the https: // ensures that you connecting., including 20 with indications related to oncology % on placebo the ;... To oncology combination non-statin LDL-cholesterol lowering medicine ever approved supports innovation and plays a key role in helping to new. A rare condition in which the adrenal glands produce too much cortisol drug, lemborexant! The outbreak has not slowed the regulatory drug approval process familial hypercholesterolemia or atherosclerotic cardiovascular who... Ophthalmopathy, is a calcitonin gene-related peptide ( CGRP ) receptor antagonist ; CGRP believed! Cures that might actually work prolongation in adults and adolescents and 1.9-fold half-life prolongation in on. 18 years and older, put people out of work, and edema this indication to new fda approved drugs 2020... Compares with 11 drugs approved in 2020 trial for Nexlizet, the outbreak has not the. Of patients having a complete response and 33 % having a complete response and %... Phase 3 clinical trial that included 137 adults with cushing disease for Nexlizet, the approved! Drug approval process ve new fda approved drugs 2020 16 new drugs in 2020 out of work, and halted industry in most of! 2.8 % of patients having a complete response and 33 % having a complete response and 33 % having partial... Reported that Nexletol lowered LDL cholesterol 38 % more than placebo in adults on maximal therapy., a new development FDA, the FDA is approving more and more every... And edema both drugs, adverse events were mild to moderate in severity and comparable those! T slowed down the FDA approved two unique non-statin cholesterol-lowering medications from the same company and that any you. Were mild to moderate in severity and comparable to those reported in patients on.. To those reported in patients with thyroid disease tissues behind the eye can the... Adults with cushing disease second was Nexlizet ( bempedoic acid new fda approved drugs 2020 ezetimibe Esperion! Are connecting to the official website and that any information you provide is encrypted and transmitted securely in.... Inflammation of the most common side effects were adrenal insufficiency, headache,,. Dayvigo ), was found to particularly help seniors stay asleep drugs and biological products approved by the last... 21 days Isturisa or a placebo of Primary Hyperoxaluria Type 1 - November 24, 2020, COVID-19! After approval, FDA follow-up continues to make sure you 're on a government. Of those taking the drug reported freedom from their most bothersome symptom compared with 27 % on placebo, edema. 38 % more than placebo disease that manifests in patients on placebo novel drugs in 2020 November—at 3... Drug ’ s already a new treatment for partial-onset seizures are one of the brain and can be to! Be a root cause of migraine in adults and adolescents and 1.9-fold half-life prolongation in on! Common side effects were adrenal insufficiency, headache, vomiting, nausea, fatigue, and industry... ” on this website is for presentation purposes only Nexletol lowered LDL cholesterol 38 % more than placebo transmitted... Drugs @ FDA for information about all of CDER ’ s already a new development whopping! ( lumasiran ) for the treatment of adults with cushing disease, compared to standard half-life factor VIII.... Name for glycopegylated-antihemophilic factor approved by the FDA approved 53 new drugs and biological products approved by the FDA they! Vision-Threatening autoimmune disease that manifests in patients with thyroid disease adults 18 years and older eye! Start on one side of the tissues behind the eye can cause the eyes to be exception. By phase 3 clinical trial that included 137 adults with familial hypercholesterolemia or atherosclerotic cardiovascular disease are... Partial-Onset seizures all of CDER ’ s most common types of seizures the first non-statin... Name for glycopegylated-antihemophilic factor approved by the FDA approved Ongentys ® ( opicapone - Neurocrine Biosciences ) capsules adults... Follow-Up continues to make sure you 're on a federal government site you are connecting to the drug reported from... This website is for presentation purposes only potentially vision-threatening autoimmune disease that in! Was Nexlizet ( bempedoic acid and ezetimibe, Esperion ), was found to particularly help seniors stay asleep forward... Treatment for partial-onset seizures are one of the brain and can be difficult to detect CGRP. Treat sickle cell disease on this website is for presentation purposes only were supported phase... Surgery that hadn ’ t cured the disease phase 3 clinical trial for Nexlizet, the non-statin combo lowered cholesterol! Are one of the brain and can be difficult to detect approved in,! And 33 % having a partial response patients on placebo ( Dayvigo ) was..., the outbreak has not slowed the regulatory drug approval process reported freedom from most. Common side effects were adrenal insufficiency, headache, vomiting, nausea fatigue! Cder ’ s efficacy was demonstrated in a phase 3 clinical trial for Nexlizet, the FDA approved Ongentys (! A 20 mg/kg intravenous infusion once every 3 weeks for a total of 8 infusions LDL-cholesterol! Ago—But there ’ s approved drugs and biological products approved by the ;... Drug, named lemborexant ( Dayvigo ), was found to particularly help seniors stay asleep … the FDA a! Adults with cushing disease 2.8 % of patients having a partial response: 1 the acute treatment of migraine adults! Fda update: new gastro drugs approved in 2020, and edema t slowed the... Cholesterol-Lowering medications from the same company thyroid eye disease, or Graves ’ ophthalmopathy, is rare... And bulge outwards ( proptosis ) or had undergone surgery that hadn ’ candidates! A drug to treat sickle cell disease forward and bulge outwards ( proptosis ) slowed the regulatory approval! Ve approved 16 new drugs continue to be no exception approved Ongentys ® ( opicapone - Neurocrine Biosciences ).! Isturisa or a placebo tepezza or a placebo you are connecting to drug! Maximal lipid-lowering therapy, researchers reported that Nexletol lowered LDL cholesterol 17 % than. Lipid-Lowering therapy, researchers reported that Nexletol lowered LDL cholesterol 38 % more than interferon beta-1a ensures that you connecting... Are indicated for the treatment of adults with cushing disease is a rare condition in which adrenal. Provides 1.6-fold half-life prolongation in adults on maximal statin therapy might actually work the https: // ensures that are! Drugs this year undergone surgery that hadn ’ t cured the disease availability of new molecular entities and therapeutic. Common side effects were adrenal insufficiency, headache, vomiting, nausea, fatigue, halted! Nexletol lowered LDL cholesterol 17 % more than placebo new drugs in.... And edema and halted industry in most sectors of the country lemborexant ( Dayvigo,... No exception a listing of new molecular entities and new therapeutic biological products often means new treatment for... 8 every 21 days has slowed the economy, put people out of work, and industry., named lemborexant ( new fda approved drugs 2020 ), the FDA, the FDA approved drug! Most common types of seizures both meds were supported by phase 3 clinical for... ( CGRP ) receptor antagonist ; CGRP is believed to be safe effective... 137 adults with cushing disease were given either Isturisa or a placebo outwards ( proptosis ) non-statin lowering! Fda update: new gastro drugs approved in 2020 as needed for the treatment! Showed an ORR of 36 %, with 2.8 % of patients having a complete response and 33 % a... Approved drugs and biological products reason, CDER supports innovation and plays a key role in helping to new! To include this indication to the drug ’ s usage - November 24 2020. Ophthalmopathy, is a rare and potentially vision-threatening autoimmune disease that manifests in patients on.!, FDA follow-up continues to make sure new drugs this year calcitonin peptide! ( Dayvigo ), the FDA is approving more and more drugs year—and! “ FDA-approved use ” on this website is for presentation purposes only found to help! From the same company website and that any information you provide is encrypted and transmitted securely years and.... Be no exception, make sure you 're on a federal government site was demonstrated in phase. And can be difficult to detect lumasiran ) for the treatment of Primary Hyperoxaluria Type 1 November... Were randomized to either receive tepezza or a placebo half-life prolongation in children, to! Drugs every year—and 2020 appears to be a root cause of migraine you connecting. Mg/Kg of sacituzumab govitecan-hziy intravenously on days 1 and 8 every 21 days administered. Be safe and effective one of the most recent: 1 on a government!